1. Introduction {#Section1}
===============

It is generally recognized that cancer has a high risk of venous thromboembolism (VTE). Deep vein thrombosis (DVT) and pulmonary embolism (PE) are collectively referred to as venous thromboembolism. Notably, lung cancer, the most frequently diagnosed cancer and the leading cause of cancer death among males all over the world, and among females in more developed countries [@B1], is the most common malignancy coexisting in patients with pulmonary embolism [@B2], [@B3], namely lung cancer is more prone to PE than other malignant tumors [@B4], [@B5]**.** Undoubtedly lung cancer is a great risk factor for development of PE**.** For example, lung cancer patients are six times more likely to have a PE compared to cancer-free controls in the 12 months before diagnosis [@B6].

Indeed, PE plays an important role in the process of lung cancer as it affects the survival time of patients. Occurrence of PE is associated with decreased survival among lung cancer patients [@B7], [@B8] and evidences of pulmonary embolism as the cause of death have been reported in 10% of patients with lung cancer at the time of postmortem examination [@B9]. Furthermore, PE plays a significant role in healthcare utilization among lung cancer patients: evidences from VTE: the overall hospital charges were higher in lung cancer patients with VTE, at a mean of \$43,800 vs. \$37,800 for those without VTE (p \< 0.001) [@B10] and the same trend was applicable to the ambulatory lung cancer patients with VTE (\$28,003 vs. \$10,914; P \< 0.0001) [@B11]. Therefore, in this article, we provided an overview of this association between lung cancer and pulmonary embolism, and summarized incidence of PE, unsuspected pulmonary embolism, risk factors and pathophysiological considerations, treatment, prognostic significance as well as prophylaxis of thrombotic events.

2. Methods {#Section2}
==========

Publications were identified through searching the PubMed from 1, 1900 to October 4, 2017. The search was supplemented by a manual search of published reviews and the strategy was designed and constructed by authors (**Table [1](#T1){ref-type="table"}**). We excluded studies having less than five original cases as well as without interesting outcomes according to screen the abstract whereas we included the cohort of patients enrolled in randomized controlled trials (RCTs), as we want to find out the incidences of pulmonary embolism in all kinds of clinical trials. Overall, we screened abstracts of articles obtained through PubMed search and hand-searched the reference list of pertinent articles. Two authors (Y.P.L and Y.S) independently screened the titles and abstracts of the identified articles and they extracted and interpreted the data independently, then in duplicate.

3. Incidence of PE in Lung Cancer Patients {#Section3}
==========================================

The incidence of PE is flexible in various studies, thereby we searched the dates about incidence of PE in patients with lung cancer, hoping to summarize an overall incidence of PE. According to the full-text paper screening, forty-one studies consisting of 13 RCTs [@B12]-[@B24], 27 retrospective cohorts [@B11], [@B25]-[@B50], 1 prospective cohort [@B51] had been selected and showed in **table [2](#T2){ref-type="table"}**.

PE is a frequent finding, with an overall incidence of 3.7% (1,172 of 31,294), ranging from 0 to 23.7% in lung cancer patients [@B11]-[@B51]. The pooled frequency of PE in RCTs is 2.3% (66 of 2,903), ranging from 1.3% to 21.4% [@B12]-[@B24], of all the highest rate (21.4%) of PE occur in the process of chemotherapy where nab-paclitaxel was used to treat patients with advanced NSCLC who failed first-line chemotherapy [@B16] followed by 8% in a RCT for the evaluation of pemetrexed plus cisplatin in combination with or without LY2603618 (a selective checkpoint kinase 1 inhibitor) in patients with advanced nonsquamous NSCLC [@B12], impling the incidence of PE in various RCTs for lung cancer patients could be high. The PE rate is lower in lung cancer patients only undergoing lung resection (1.6%, 59 of 3,718, range: 0-2.7%) [@B25]-[@B27], [@B29], [@B34], [@B37], [@B41], [@B43], [@B45], [@B46] than those only receiving nonsurgical therapy (5.0%, 618 of 12,239, range: 1.3%-21.4%) [@B11]-[@B21], [@B23], [@B24], [@B28], [@B32], [@B33], [@B36], [@B44], [@B51], yet than those receiving comprehensive therapy (surgical and nonsurgical) (2.5%, 279 of 10,962, range: 0-13.3%) [@B22], [@B30], [@B35], [@B38], [@B39], [@B47]-[@B50]. These results imply that the risk of PE in lung cancer patients receiving nonsurgical therapy is higher than those only undergoing lung resection. Furthermore, the overall frequency of PE in patients undergoing video-assisted thoracoscopic surgery (VATS) or robotic-assisted video thoracoscopic surgery (RAVTS) for lung cancer is 0.5% varying between 0 and 2% [@B26], [@B27], [@B29], [@B34], [@B37], [@B45], implying VATS or RAVTS is feasible in lung cancer.

The majority of patients were male (15,754, 61.4%) and the mean age was 62.5 years, ranging from 19 to 93 [@B11], [@B13]-[@B24], [@B26], [@B28], [@B29], [@B31]-[@B41], [@B43]-[@B45], [@B47]-[@B51]. We also found that major patients only receiving surgery for lung cancer had stage I/II but those receiving nonsurgical conditions had stage III/IV according to **table [2](#T2){ref-type="table"}**, which might be one of causes of higher rate of PE in lung cancer patients with nonsurgical therapy.

In a review of lung cancer patients undergoing lung resection [@B7], despite whether the patients underwent chemotherapy or radiotherapy or both, the overall frequency of PE in 10,660 patients was 1.2% (slightly lower than our finding), and Christensen and colleagues also found the mean risk of PE was 1.8% in lung cancer patients where antithrombotic prophylaxis was used.

4. Unsuspected Pulmonary Embolism {#Section4}
=================================

Many lung cancer-associated PE events are found incidentally on radiographic testing performed for diagnostic or staging purposes and treatment response evaluation to lung cancer patients, which has been described as unsuspected pulmonary embolism (UPE). In several studies, 29.4%, 37.5%, 40%, 63% of PE in lung cancer patients are respectively and incidentally diagnosed [@B8], [@B39], [@B50], [@B52]. And the performances of imaging are very contrastive: suspected PE more commonly involves main/lobar pulmonary arteries (73% versus 28%, p = 0.0001) whereas UPE more frequently involves segmental arteries (38% vs. 11%, p = 0.01) [@B42]. Besides, adenocarcinoma and frequency of anti-cancer therapeutic agents are more common in the clinically unsuspected group, conversely, squamous cell carcinoma is more common in the clinically suspected group (24% versus 0%, p = 0.002). However, age, presence of metastatic disease, gender at the time of PE or treatment for PE are similar in the both groups [@B42].

5. Risk Factors and Pathophysiological Considerations {#Section5}
=====================================================

PE resulted from a combination of the following: vascular endothelial damage, stasis of blood flow, and hypercoagulability. These factors appear to be present in lung cancer patients and can be classified as: lung cancer-related, patient-related and treatment-related factors (**Fig. [1](#F1){ref-type="fig"}**).

5.1. Hypercoagulability {#Section5.1}
-----------------------

Both Intrinsic pathway (INTEM) and extrinsic pathway (EXTEM) participate in coagulation. Hypercoagulability have been described for an imbalance between procoagulant and anticoagulant factors and could contribute to pulmonary embolism in patients with lung cancer. Studies have uncovered some risk factors in patients with lung cancer that can contribute to the hypercoagulability, including decreased clot formation time (both in INTEM and EXTEM), elevated maximum clot firmness and alpha angle, higher levels of fibrinogen and platelets [@B53] as well as increased prothrombin fragment 1 + 2 (F 1 + 2; a marker of thrombin generation) and thrombin-activatable fibrinolysis inhibitor immunologic activity level (inhibition of the fibrinolytic system) [@B54]. Tissue factor (TF), the initiator of the clotting cascade, over expresses in lung cancer cells, which implies that TF is an activator of coagulation in the wide array of lung cancer cells [@B55]. In addition, platelets after chemotherapy had elevated PCA (procoagulant activity) and may contribute to the hypercoagulability of non-small cell lung cancer (NSCLC) [@B56].

5.2. Lung Cancer-Related Risk Factors {#Section5.2}
-------------------------------------

### 5.2.1. Histological type {#Section5.2.1}

Multivariate analysis finds NSCLC is at high risk of PE in lung cancer patients (OR, 2.88; 95% CI: 1.97-3.78, p = 0.008) [@B57]. In particular, adenocarcinoma, one of subtypes of NSCLC, is an independent risk factor for development of PE in lung cancer patients [@B32], [@B58]-[@B61]. Both platelet activation and thrombin generation processes could contribute to blood hypercoagulability according to lead to the expression of procoagulant phospholipids and the release of phosphatidylserine expressing microparticles in primary non-metastatic localized lung adenocarcinoma [@B62].

### 5.2.2. Stage of lung cancer {#Section5.2.2}

Advanced stage (stage III to IV) at initial diagnosis of lung cancer is an independent risk factor associated with PE [@B59], [@B63]. Another study also confirmed that stage IV or extensive disease (stage of SCLC) is independent risk factors of PE (OR, 1.9; 95% CI: 1.4-2.6, p \< 0.001) [@B50]. Furthermore, in univariate analysis, brain or leptomeningeal metastasis are associated with a significant higher risk of PE in lung cancer patients (p \< 0.001) whereas in multivariate analysis, the association seems to be weak (OR, 1.4; 95% CI: 0.98-2.0, p = 0.06) [@B50]. Lung cancer patients with stage III/IV have lower clot time and higher plasminogen activator inhibitor (PAI-1) level compared to those with stage I/II (p \< 0.05) [@B53], which could be the cause of higher risk of PE in lung cancer patients with stage III/IV.

### 5.2.3. Other risk factors {#Section5.2.3}

The highest incidence of PE occurs within 6 months of the diagnosis of lung cancer (hazard ratio \[HR\], 16.8; 95% CI: 7.6-36.8; after adjustment for antihypertensive drugs), thereafter, the risk falls (HR, 5.1; 95 % CI: 2.7-9.4) [@B6]. In terms of three oncogene drivers: EGFR (epidermal growth factor receptor) mutations, KRAS (KRAS proto-oncogene, GTPase) mutations and EML4/ALK (ALK receptor tyrosine kinase) rearrangements in lung cancer patients, the presence of EML4/ALK rearrangements is associated with a 2-fold high risk of PE (HR, 2.06; 95% CI: 1.08-3.55) whereas risk of PE is not found to be associated with EGFR or KRAS mutations [@B31]. Indeed, ELM4/ALK rearrangements lead to expression of a potent tyrosine kinase that is able to enhance the TF procoagulant activity [@B64], [@B65].

5.3. Patient-Related Risk Factors {#Section5.3}
---------------------------------

### 5.3.1. Comorbid conditions {#Section5.3.1}

Studies have uncovered some comorbid conditions in patients with lung cancer that can contribute to the development of PE, including anemia (Hemoglobin ≤ 100 g/L) [@B32], [@B58], [@B66], obesity \[body mass index (BMI) ≥ 30\] among patients with primary lung cancer undergoing lobectomy (1.5% vs. 0.8%, P = 0.005) [@B67], chronic obstructive pulmonary disease (COPD) [@B63] and DVT (OR, 10.62; 95% CI: 4.94-18.08, p \< 0.001) [@B57]. However, Ma et al. suggested that comorbidities such as diabetes, hypertension, pulmonary tuberculosis and cardiovascular disease were not risk factors of PE in patients with lung cancer (p \> 0.05) [@B59].

### 5.3.2. Blood parameters {#Section5.3.2}

Multivariate analysis indicates that serum hemoglobin \> 140 g/L is at high risk for development of PE in lung cancer patients (OR, 2.10; 95% CI: 1.44-3.08, p = 0.03), which could result from stasis of blood flow due to higher blood viscosity [@B63]. In addition, white blood cell (WBC) \> 11×10^9^/L, D-dimer \> 500 μg/L (OR, 3.15; 95% CI: 2.044-3.863, p = 0.025), PaO~2~ \< 80 mmHg are respectively the independent risk factors of PE in lung cancer patients [@B58]. Another two studies also show that different D-dimer levels (865 ± 489 μg/L, OR = 2.7 or 2,670 ± 1,350 μg/L, OR = 6.16) are independent risk factors of PE [@B57], [@B59], which implies the D-dimer level could be positively associated with the risk of PE.

In terms of tumor markers (TMs) panel: carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCC), cytokeratin 19 fragment (CYFRA21-1), neuron-specific enolase (NSE) and progastrin-releasing peptide (ProGRP), the multivariate logistic analysis demonstrates that TMs panel (OR, 5.98; 95% CI: 2.36-9.04, P \< 0.001) has significant correlation with PE and the AUC (area under curve) is 0.82 (95% CI: 0.71-0.95, P \< 0.001) according to ROC (receiver operating characteristic) curve analysis, meanwhile, not less than 3 abnormal values in the five TMs is the optimal cutoff value to assist the diagnosis of PE with both high sensitivity and specificity (81.6% and 83.8%, respectively) [@B57]. For individual TMs, CEA is the most relevant one with PE and the AUC is 0.71 or 0.68 according to ROC curve analysis [@B32], [@B57]. The number of abnormal TMs is positive correlation of D-dimer level (P trend \< 0.001) in lung cancer patients with PE, the same trend is applicable to CEA (R^2^ = 0.735, P = 0.003) and CYFRA21-1 (R^2^ = 0.718, P = 0.005) [@B57], which could contribute to the development of PE.

### 5.3.3. Other risk factors {#Section5.3.3}

Immobilization could contribute to the development of PE in lung cancer patients [@B68] according to lead to stasis of blood flow. In addition, female sex is also associated with a significantly higher risk of PE in lung cancer patients (p \< 0.0001) according to univariate analysis whereas in multivariate analysis, the association seems to be weak (OR, 1.2; 95% CI: 0.9-1.7, p = 0.2) [@B50]. Moreover, hospitalization in the 12 months before diagnosis of lung cancer is remarkably correlated with occurrence of PE after diagnosis (HR, 50; 95% CI: 12-203; after adjustment for age and gender) [@B6]. Although smoking is associated with development of PE in general population, it is not a risk factor of PE in lung cancer patients [@B57], [@B59], [@B63].

5.4. Treatment-Related Risk Factors {#Section5.4}
-----------------------------------

### 5.4.1 Surgery {#Section5.4.1}

Surgery is associated with increased risk of PE in lung cancer patients (OR, 4.33; 95% CI: 2.36-4.92, p \< 0.001) [@B57] even in patients receiving antithrombotic prophylaxis, there seems to be a substantial risk of PE [@B29], [@B43]. The results suggest that despite thromboprophylaxis, surgery is an important risk factor of PE in lung cancer patients. Furthermore, the risk of PE developing within the first month postoperatively is 1.3%, similar to 1.1% after 1 month of observation time, which could indicate that PE predominantly occurs within the initial postoperative period, and subsequently the risk falls [@B7]. Increased hypercoagulability (elevated D-dimer level and F1 + 2 concentrations) within the first 9-10 postoperative days [@B69], [@B70] could contribute to the development of PE in NSCLC patients.

Increased risk of pulmonary embolism in patients undergoing surgery for lung cancer involve extensive surgical intervention, the intrinsic procoagulant effect of lung cancer, vessel injury due to the operation, and dependent limb position in the operating room [@B43]. In addition, lung cancer patients undergoing pneumonectomy are at higher risk of PE than those having lobectomy or segmental resection and massive pulmonary embolism is a frequent early postoperative fatal complication after lung resections, which can\'t be safely prevented by postoperative heparinization [@B71].

### 5.4.2. Chemotherapy {#Section5.4.2}

Chemotherapy is an independent risk factor for the development of PE in lung cancer patient (OR, 2.0; 95% CI: 1.5-2.8, p \< 0.001) in multivariate analysis [@B50], which is also confirmed (OR, 2.64; 95% CI: 1.78-3.89, p \< 0.01) by another study [@B63]. And the correlation between risk of PE and cisplatin-based chemotherapy has been observed (HR, 1.51; 95% CI: 1.12-2.36) [@B31]. Lung cancer chemotherapy agents such as cisplatin, carboplatin, gemcitabine and paclitaxel increase procoagulant activity on endothelial cells by TF decryption through a disulfide bond formation in a PDI-dependent (protein disulfide isomerase) mechanism [@B72], and could have a thrombogenic effect due to direct endothelial lesion [@B73].

Target drugs can cause PE, for example, bevacizumab, the monoclonal antibody to vascular endothelial growth factor (VEGF), is associated with development of PE in lung cancer patients particularly in patients with SCLC [@B74]. Plasminogen activator inhibitor (PAI-1) expression in tumors, plasma, and thrombi could contribute to the bevacizumab\'s prothrombotic effect in a mouse xenograft model of human lung carcinoma, which indicates the inhibition of PAI-1 as a therapeutic strategy for the prevention of bevacizumab-associated VTE is efficient [@B75].

### 5.4.3. Central venous catheters (CVC) {#Section5.4.3}

CVC is at high risk of PE in lung cancer patients (OR, 2.00; 95% CI: 1.07-3.74, p = 0.03) whereas in multivariate analysis, the association seems to be weak (OR, 1.76; 95% CI: 0.99-2.76, p = 0.09) [@B63].

6. PE Treatment {#Section6}
===============

ESC (The European Society of Cardiology) recommends that low-molecular-weight heparin (LMWH) administered in the acute phase (except for high-risk PE) and continued over the first 3-6 months should be considered as first-line therapy in patients with cancer and acute PE [@B76]. And, chronic anticoagulation may consist of continuation of LMWH, transition to vitamin K antagonist (VKA), or discontinuation of anticoagulation [@B76].

PE can be treated only with unfractionated heparin (UFH) sodium followed by warfarin if the diagnosis of PE was confirmed and start the treatment immediately after the first episode in patients after operation for lung cancer [@B77]. And, another study also verified such patients could be treated aggressively with anticoagulants with/without fibrinolytics or even with pulmonary embolectomy on cardiopulmonary bypass, without excessive risk of bleeding complications [@B46].

In addition, clinicians should pay attention on cancer embolus occurred in the process of metastasis of lung cancer cells [@B78] as the efficiency of anticoagulation or thrombolytic therapy is poor while chemotherapy may be efficient.

Little evidence is available for treatment of lung cancer-related PE with the new oral anticoagulants.

The assessment of risk-benefit ratio
------------------------------------

During the course of anticoagulant therapy, the main safety outcome is hemorrhage (major bleeding and minor bleeding) whereas prevention of PE recurrence or progression is also vital. Therefore, to reassess the risk-benefit ratio of anticoagulant treatment is an efficient strategy for patients with lung cancer and PE. In the process of anticoagulant therapy (mean duration, 139 days), the rate of PE recurrences was slightly higher than the rate of major bleeding (14 vs. 11 per 100 patient-years) in patients with lung cancer and PE [@B79]. Another study also indicated that the rate of major bleeding was 3% in lung cancer patients with PE receiving anticoagulation [@B42].

In addition, the use of argatroban in conjunction with activated clotting time monitoring should be effective without causing bleeding problems during the early stages after pulmonary resection for lung cancer [@B46]. Besides, venous filters should primarily be considered when anticoagulation is impossible due to hemorrhage; however, the risk of filter thrombosis in the absence of anticoagulation may be particularly high in cancer patients [@B76].

7. Prognostic Significance {#Section7}
==========================

The mean survival time in lung cancer patients with PE is remarkably shorter than those without PE [@B7], [@B8], [@B50], [@B52], [@B58], [@B63], [@B66], [@B80], even in lung cancer patients with PE who all received UFH intravenously or LMWH subcutaneously, followed by an oral anticoagulant, the survival time is still significantly shorter than only those [@B59]. Furthermore, patients with PE and lung cancer diagnosed concomitantly have also significantly shorter mean survival time compared with matched controls (110.5 vs. 183.5 days, p = 0.003), but those with PE diagnosed after the diagnosis of lung cancer have no this difference (312 vs. 477 days, p = 0.206) [@B80]. Another study found that PE detected within 3 months after diagnosis of lung cancer was significantly associated with shorter mean survival (8.9 months vs. 22.5 months; HR, 1.5; 95% CI: 1.1-2.0; after adjustment for gender, age, histology, and initial cancer stage) compared with remainder lung cancer patients [@B50].

Only for lung cancer patients with UPE, no receiving anticoagulation therapy has a 4.1-fold (95% CI, 2.3-7.6) increase in mortality compared to those having received anticoagulation therapy [@B50]. Compared to lung cancer patients with suspected PE (4.2 months \[95% CI, 2.6-5.8 months\]), those with UPE \[9.3 months (95% CI, 5.7-13.0 months)\] have higher median overall survival (P = 0.001), even when anticoagulation therapy is administered to 99% of suspected PE patients and 45% of UPE patients, respectively (P \< 0.001 using the Chi-square test) [@B50]. And, the remarkable difference in the overall survival between the two groups is still present (HR, 1.7; 95% CI: 1.1-2.6) after adjustment for other prognostic factors such as cancer stage and performance status at the time of diagnosis of PE [@B50]. However, another study denied the difference, finding median survival was similar between suspected PE group (5.6 months) and unsuspected PE group (6.2 month) in univariate and multivariate analyses [@B42]. Although the two studies showed different consequences, we couldn\'t ignore the importance of UPE in lung cancer patients.

Mortality is ascending in lung cancer patients with PE even if most patients died of cancer progression [@B52], [@B59], [@B81], thereby when the clinical presentation and objective tests raise the suspicion of PE in an individual patient, clinicians should prompt further objective testing to confirm PE, and we shouldn\'t relax our vigilance against UPE.

8. Prophylaxis of Thrombotic Events {#Section8}
===================================

8.1. Prophylaxis for Surgery {#Section8.1}
----------------------------

Prophylactic anticoagulation preferably as LMWH or low-dose unfractionated heparin (LDUH) or fondaparinux should be given to all patients who underwent surgical producers for cancer perioperatively, and continue at least for 7 to 10 days unless contraindication occur: a high risk for active bleeding [@B82]. And, it could be better to continue up to 4 weeks for these patients with high-risk features such as residual disease, obesity, or prior VTE [@B82].

In addition, in a study of patients with primary lung cancer patients undergoing lung resection, three eligibility criteria \[**1**) For the operation day, LDUH 5,000 unit every 12 hours; if diffuse adhesion in the thoracic cavity was observed or intraoperative blood loss \> 500 ml, discontinue LDUH administration. **2)** For the postoperative period, LDUH 5,000 unit every 12 hours; if the postoperative bleeding was over 400 ml on the operation day or the patient\'s body weight was less than 40 kg, LDUH 2,500 unit every 12 hours. **3)** Discontinue anticoagulation until the day when the patient could walk around the floor\] was introduced and the efficacy had been certified [@B83]. And, In a large multicenter trial, that low-dose heparin (5,000 units) administered 2 hours before incision and then every 8 hours postoperatively dramatically reduced the incidence of VTE [@B84].

Furthermore, the appropriate preoperative usage of heparin enables the standard surgical treatment of lung cancer patients with cardiovascular complications, so Notsuda et al. recommend the use of LMWH or LDUH as the antithrombotic agent before lung cancer surgery especially for those with cardiovascular complications [@B85].

Some studies also found that huisheng oral solution \[HSOS, a traditional Chinese medicine preparation; 20 mL, tid (three times a day)\] and preoperative insertion of inferior vena cava filter (IVC filter) were of good safety profiles for prophylaxis of PE [@B86], [@B87].

8.2. The Assessment of Risk-benefit Ratio for Anticoagulant Therapy {#Section8.2}
-------------------------------------------------------------------

Anticoagulant therapy significantly prolongs life expectance and decreases the risk of VTE for patients with non-advanced/limited lung cancer (risk ratio \[RR\], 1.30; 95% CI: 1.03-1.65; p = 0.03), especially those with SCLC (RR, 1.21; 95% CI: 1.07-1.38; p = 0.003), but not in those with NSCLC (p = 0.78) [@B88]. Another study also found anticoagulation (LMWH, UFH, warfarin) showed a pooled mortality benefit, and no significant difference between LMWH and warfarin [@B89]. Furthermore, the clinical trials of anticoagulation in addition to chemotherapy suggested a survival benefit among patients with SCLC [@B90]-[@B92]. Therefore, anticoagulation is useful for prophylaxis of PE in lung cancer patients, especially in patients with limited SCLC, but it not only carries an intrinsic and clinical relevant risk of major bleeding but also is expensive [@B93], [@B94], implying the importance of assessment of risk-benefit ratio.

### 8.2.1. Warfarin {#Section8.2.1}

Warfarin increased risk of bleeding in patients with lung cancer (RR, 5.14, 95% CI: 1.66 to 15.94; p = 0.005) [@B88]. And, compared to LMWH and unfractionated heparin groups in lung cancer patients, the greatest odds of bleeding was found in the warfarin group (OR, 5.42; 95% CI: 3.48-8.45) [@B89]. The estimate of warfarin for mortality in all SCLC was statistically significant at six months (RR, 0.69; 95% CI: 0.50-0.96, p = 0.028) but not at one year (RR, 0.88; 95% CI: 0.77 to 1.01, p = 0.070), meanwhile, a significant increased risk of major bleeding (RR, 5.46; 95% CI: 3.04-9.81, p \< 0.000001) and minor bleeding (RR, 4.01; 95% CI: 1.30-12.42, p = 0.016) has been obtained [@B95]. Furthermore, warfarin plus chemotherapy don\'t demonstrate the survival advantage in patients with SCLC because of the more warfarin-related deaths [@B96].

### 8.2.2. Heparin {#Section8.2.2}

Primary prophylaxis with LMWH (at least for 6 weeks) reduces the incidence of PE in lung cancer patients [@B89], especially in those receiving chemotherapy [@B97], [@B98]. In patients with limited SCLC, heparin including unfractionated heparin (UFH) and LMWH (prophylactic dose for at least 5 weeks) suggests a survival benefit (HR, 0.56; 95% CI: 0.38-0.83, p = 0.004) whereas no significant survival benefit is observed in patients with extensive SCLC or advanced lung cancer (HR, 0.80; 95% CI: 0.60-1.06, p = 0.12) [@B99]. In addition, patients with NSCLC stage IV had a statistically significant reduction in VTE rate with LMWH (throughout induction chemotherapy) compared with placebo group (3.5% vs. 10.2%, OR, 0.32; 95% CI: 0.09-0.98; p = 0.032), in contrast, the stage III group receiving LMWH thromboprophylaxis did not reduce the incidence of VTE compared to placebo (5.7% and 6.4%, respectively) [@B100]. It\'s important that many studies found that increased risk of bleeding wasn\'t noted for heparin in lung cancer patients [@B88], [@B89], [@B97], [@B99], therefore heparin is a suitable choice for prophylaxis.

9. Comment {#Section9}
==========

There is a significant relationship between lung cancer and PE, while very little references were known about PE and lung cancer. Furthermore, this relationship is further confused because respiratory distress in lung cancer patients is often attributed to pneumonia, disease progression, malignant pleural effusion or other complications, which may contribute to the high incidence of UPE (range 29.4%-63%). Characteristics of patients with lung cancer such as adenocarcinoma and the usage of anti-cancer drug are more prone to have a harboring PE. What\'s more, the incidence of PE may be underestimated with the decrease of the overall number of autopsies performed worldwide, especially for lung cancer patients of sudden death.

Anyway, studying based on the literature, the rates of PE in patients with lung cancer remain high across all patients with cancer, with an overall incidence frequency of 3.7%. Of all, lung cancer patients receiving nonsurgical therapy have higher rate of PE compared with those only receiving surgical therapy \[5.0% (only nonsurgical), 2.5% (nonsurgical + surgical) vs. 1.6%\] and a high overall incidence of PE has also been found in RCTs (2.3%). When lung cancer was diagnosed, many therapeutic interventions such as surgical series and nonoperative series were implemented according to the stage and histological type of lung cancer, which reflects the differences of occurrence of PE. For example, patients with advanced stages of cancer are not surgical candidates whereas they have higher risk for the development of PE. Besides, blood parameters such D-dimer, PaO~2~, and tumor markers (CEA, SCC, CYFRA21-1, NSE and ProGRP) etc. seem to be the predictors of PE, and not less than 3 abnormal values in the five TMs [@B57] is the optimal cutoff value to assist the diagnosis of PE with both high sensitivity and specificity. Indeed, many risk factors of PE in lung cancer patients are correlative and promote the occurrence together in clinical work.

Although the treatment of PE has been more and more normative in lung cancer patients, when it occurs, survival time is significantly decreased. Especially, UPE has also a decreased survival time in lung cancer patients whereas we usually neglect it in clinical work, thereby whether objective testing for PE should be the routine testing in lung cancer patients need more studies to assess. According to scan some references, we could draw a conclusion that heparin seems superior to VKA for thrombotic prophylaxis, and prophylactic anticoagulant therapy benefit might be highest in patients with stage IV NSCLC or limited SCLC. Furthermore, we summarized the prophylactic anticoagulation for lung cancer and gave a recommendation (**Fig. [2](#F2){ref-type="fig"}**), of which the main safety outcome was hemorrhage (major bleeding and minor bleeding). However, such a recommendation, albeit plausible, has not been tested in randomized trials and needs further investigation.

10. Future Recommendations {#Section10}
==========================

Drug therapy of lung cancer seems to be a powerful risk factor for PE, however, thrombotic risk of every chemotherapeutic drug and targeted drug in lung cancer patients has not been studied extensively. In addition, new oral anticoagulants are very efficient in patients with PE, however, the efficiency of them in patients with cancer especially lung cancer has not been estimated. Notably, large, high quality outcome trials on the optimal prophylaxis and treatment of PE in lung cancer patients are lacking and the assessment for the safety of the new oral anticoagulants is also limited, which warrants further investigation.

In conclusion, this study demonstrated the association between lung cancer and PE, showing the high incidence of PE in lung cancer patients. When PE occurs, it could be fatal and affect survival, thereby, it is necessary for us to understand the risk factors and master its prophylaxis. As for treatment, the main safety outcome of anticoagulant therapy was hemorrhage, thereby risk assessment will remain the cornerstone of the PE therapeutic management. There is no doubt that selection of lung cancer patients for early diagnose or treatment of PE will probably be more efficient, which could increase mean survival time.
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:   vitamin K antagonist

EGFR

:   epidermal growth factor receptor

KRAS

:   KRAS proto-oncogene, GTPase

ALK

:   ALK receptor tyrosine kinase

INTEM

:   Intrinsic pathway

EXTEM

:   extrinsic pathway

VATS

:   video-assisted thoracoscopic surgery

RAVTS

:   robotic-assisted video thoracoscopic surgery

AUC

:   area under curve

ROC

:   receiver operating characteristic

PDI

:   protein disulfide isomerase

PAI-1

:   plasminogen activator inhibitor

CVC

:   central venous catheters.

![Pathophysiological link between lung cancer and pulmonary embolism. NOTE: CVC: central venous catheters; CEA: serum carcinoembryonic antigen; WBC: white blood cell; COPD: chronic obstructive pulmonary disease; DVT: deep vein thrombosis; PE: pulmonary embolism; PCA: procoagulant activity; TF: tissue factor; F 1 + 2: prothrombin fragment 1 + 2; BMI: body mass index; NSCLC: non-small cell lung cancer; SCC: squamous cell carcinoma antigen; CYFRA21-1: cytokeratin 19 fragment; NSE: neuron-specific enolase; ProGRP: progastrin-releasing peptide; TMs: tumor markers.](jcav09p3046g001){#F1}

![Prophylactic anticoagulation in lung cancer patients. NOTE: When PE is confirmed in the process of prophylactic anticoagulation, treatment should be taken quickly. LDUH: low-dose unfractionated heparin; LMWH: lower-molecular-weight heparin; HSOS: huisheng oral solution; IVC filter: Inferior vena cava filter; UFH: unfractionated heparin.](jcav09p3046g002){#F2}

###### 

Searched strategy for PubMed

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  PubMed was searched from 1 January 1900 to 4 October 2017, using the following search strategy:\
  1. "Pulmonary embolism" \[MeSH Terms:NoExp\] OR lung embolism\*\[tiab\] OR pulmonary embolism\*\[tiab\] OR pulmonary thromboembolism\*\[tiab\] (n = 47,689)\
  2. \"Lung Neoplasms\"\[MeSH:NoExp\] OR lung carcinoma\* \[tiab\] OR \"Carcinoma, Bronchogenic\"\[Mesh\] OR Bronchogenic cancer\* \[tiab\] OR Bronchogenic carcinoma\* \[tiab\] OR lung cancer\* \[tiab\] OR pulmonary cancer\* \[tiab\] OR pulmonary carcinoma\* \[tiab\] OR (\"Adenocarcinoma, Bronchiolo-Alveolar\"\[Mesh\] or lung adenocarcinoma\* \[tiab\] OR pulmonary adenocarcinoma\* \[tiab\] or Bronchiolo-Alveolar adenocarcinoma\* \[tiab\]) OR (lung Squamous Carcinoma\* \[tiab\] OR pulmonary Squamous Carcinoma\* \[tiab) OR lung Large cell carcinoma \[tiab\] OR adenosquamous carcinoma of the lung \[tiab\] (n = 241,235)\
  3. \"1900/01/01\"\[pdat\] : \"2017/10/04\"\[pdat\] (n = 27,711,426)\
  4. 1 AND 2 AND 3 (n = 1,236)\
  5. Review\[ptyp\] OR letter\[ptyp\] OR editorial\[ptyp\] OR case reports\[ptyp\] (n = 5,267,472)\
  6. 4 NOT 5 (n = 635)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Coexisting PE reported in patients with lung cancer**.**

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author, year             Population description   Study design    Total\   PE, n (%)   Type of lung cancer   NSCLC, n   Number of stages (%)                                                                 Age, Years, Mean (range)   No. of male (%)   Country of Origin
                                                                          N                                                                                                                                                                                       
  ------------------------------ ------------------------ --------------- -------- ----------- --------------------- ---------- ------------------------------------------------------------------------------------ -------------------------- ----------------- ------------------------
  Wehler **[@B12]**, 2017        Nonsurgical              RCT             62       5 (8.0)     NSCLC                 62         IV = 62                                                                              NR                         NR                Germany and Spain

  Moon **[@B25]**, 2017          Surgical                 Retrospective   1,196    33 (2.7)    NR                    NR         NR                                                                                   NR                         NR                Korea

  Fred **[@B13]**, 2017          Nonsurgical              RCT             106      3 (3.0)     NSCLC                 106        NR                                                                                   67 (42-84)                 79 (72)           Unite States et al.

  Levy **[@B14]**, 2016          Nonsurgical              RCT             16       1 (6.0)     NSCLC                 16         IIIB = 16                                                                            55.5 (43-70)               12 (75)           France

  Goss **[@B15]**, 2016          Nonsurgical              RCT             199      7 (3.0)     NSCLC                 199        NR                                                                                   64 (35-88)                 64 (32)           Canada et al.

  Glover **[@B26]**, 2016        Surgical                 Retrospective   52       1 (2.0)     NSCLC                 52         II = 11 (21), III = 36 (69), IV = 5 (10)                                             67.2 (48.0-86.0)           30 (57.7)         Unite States

  Mungo **[@B27]**, 2016         Surgical                 Retrospective   133      0 (0)       NSCLC                 133        I = 126 (94.7), II + III = 7 (5.3)                                                   66.7 (60-74)               NR                Unite States

  Michelsen **[@B28]**, 2015     Nonsurgical              Retrospective   42       5 (11.9)    NSCLC                 42         IIIB = 2 (4.8), IV = 40 (95.2)                                                       62 (23-74)                 17 (40.5)         Denmark

  Sandri **[@B29]**, 2015        Surgical                 Retrospective   227      2 (0.9)     NR                    NR         NR                                                                                   67.9                       106 (47)          United Kingdom

  Hu **[@B16]**, 2015            Nonsurgical              RCT             56       12 (21.4)   NSCLC                 56         NR                                                                                   59.6 (32-83)               31 (55.4)         China

  Cukic **[@B30]**, 2015         Nonsurgical + Surgical   Retrospective   1,609    42 (2.6)    NSCLC +SCLC           NR         NR                                                                                   NR                         NR                Bosnia and Herzegovina

  Verso **[@B31]**, 2015         NR                       Retrospective   173      41 (23.7)   NSCLC                 173        IIIB = 18 (10.4), IV = 155 (89.6)                                                    62.4                       104 (60.1)        Italy

  Karavasilis **[@B17]**, 2014   Nonsurgical              RCT             50       1 (2.0)     NSCLC                 50         NR                                                                                   62.5 (43-74)               39 (78)           Greece

  Zhang Y **[@B32]**, 2014       Nonsurgical              Retrospective   673      47 (7.0)    NSCLC +SCLC           565        NR                                                                                   64                         486 (72.2)        China

  Dingemans **[@B18]**, 2014     Nonsurgical              RCT             25       1 (4.0)     NSCLC                 25         III = 25                                                                             59 (45-72)                 12 (48)           Belgium

  Mellema **[@B33]**, 2014       Nonsurgical              Retrospective   784      25 (3.2)    NSCLC                 784        I-IIB = 42 (5.4), IIIA = 197 (25.1), IIIB = 199 (25.4), IV = 346 (44.1)              59.5 ± 10.6                504 (64.3)        Netherlands

  Wang **[@B34]**, 2014          Surgical                 Retrospective   525      1 (0.2)     NR                    NR         I = 321 (61.4), II = 204 (38.9)                                                      NR                         289 (55.0)        China

  Kadlec **[@B35]**, 2014        Nonsurgical + Surgical   Retrospective   950      34 (3.6)    NSCLC +SCLC           662        I = 80 (8.4), II = 76 (8), III = 274 (28.8), IV = 393 (41.4), Unknown = 127 (13.4)   64                         600 (63.2)        Czech Republic

  Nguyen **[@B36]**, 2013        Nonsurgical              Retrospective   9        1 (11.0)    SCLC                  0          IIIA = 6 (66.7), IIIB = 3 (33.3)                                                     60 (46-84)                 7 (77.8)          Unite States

  Yu **[@B37]**, 2013            Surgical                 Retrospective   21       0 (0)       NSCLC                 21         NR                                                                                   56.4 ± 3.6                 15 (71.4)         China

  Luo **[@B38]**, 2013           Nonsurgical + surgical   Retrospective   52       0 (0)       NSCLC + SCLC          24         III = 33 (63.5), IV = 19 (36.5)                                                      65 (42-75)                 41 (78.8)         China

  Powell **[@B19]**, 2013        Nonsurgical              RCT             42       1 (2.4)     NSCLC                 42         IIIB = 3 (7.1), IV = 39 (92.8)                                                       62.5 (36-80)               18 (42.9)         Unite States

  Connolly **[@B39]**, 2013      Nonsurgical + Surgical   Retrospective   207      17 (8.2)    NSCLC +SCLC           193        I = 61 (29.4), II = 16 (7.7), III = 33 (15.9), IV = 91 (43.9), Unknown = 6 (2.9)     66 (28-89)                 92 (44)           Unite States

  Crolow **[@B40]**, 2013        NR                       Retrospective   1,940    98 (5.0)    NSCLC +SCLC           1,784      I = 334 (17), II = 206 (11), III = 547 (28), IV = 818 (42), Unknown = 35 (2)         66 (19-93)                 1,209 (62)        Germany

  Dhakal **[@B41]**, 2013        Surgical                 Retrospective   320      4 (1.25)    NSCLC                 320        NR                                                                                   67 (25-88)                 135 (42.2)        Unite States

  Mountzios **[@B20]**, 2012     Nonsurgical              RCT             30       1 (3.3)     SCLC                  0          NR                                                                                   64 (43-82)                 27 (90)           Greece

  Shinagare **[@B42]**, 2012     NR                       Retrospective   2,262    77 (3.4)    NR                    NR         NR                                                                                   NR                         NR                Unite States

  Connolly **[@B11]**, 2012      Nonsurgical              Retrospective   6,732    441 (6.5)   NR                    NR         NR                                                                                   63.6                       3,329 (49.5)      Unite States

  Sun JM **[@B50]**, 2010        Nonsurgical + Surgical   Retrospective   8,014    180 (2.2)   NSCLC +SCLC           7,272      IV = 3,494 (43), I-III = 4,075 (51), Unknown = 445 (6)                               NR                         5,784 (72)        Republic of Korea

  Crinò **[@B21]**, 2010         Nonsurgical              RCT             2,212    30 (1.3)    NSCLC                 2,212      IIIB = 436 (20), IV = 1,775 (80)                                                     58.8 (24-86)               1,329 (60)        Italy

  Altorki **[@B22]**, 2010       Nonsurgical + surgical   RCT             35       1 (2.8)     NSCLC                 35         IA = 19 (54), IB = 14 (40), IIA = 1 (3), IIB = 1 (3)                                 64 (49-81)                 13 (37.1)         Unite States

  Dentali **[@B43]**, 2008       Surgical                 Retrospective   693      9 (1.3)     NR                    NR         NR                                                                                   66.7 (23-90)               418 (60.6)        Italy

  Numico **[@B51]**, 2005        Nonsurgical              Prospective     108      3 (2.8)     NSCLC                 108        III = 41 (38.0), IV = 67 (52.0)                                                      63.6 (38-76)               87 (80.5)         Italy

  Behrendt **[@B44]**, 2003      Nonsurgical              Retrospective   1,023    31 (3.0)    NSCLC                 1,023      IV = 687 (67.3), recurrent = 120 (11.8), IIIB = 213 (20.9)                           66.1 ± 10.0                665 (65.0)        Unite States

  G. F **[@B45]**, 2003          Surgical                 Retrospective   179      2 (1.1)     NSCLC                 179        IA = 118 (65.9), IB = 61 (34.1)                                                      64.3 (38-87)               88 (49.1)         Unite States

  Sakuragi **[@B46]**, 2003      Surgical                 Retrospective   372      7 (1.9)     NR                    NR         NR                                                                                   NR                         NR                Japan

  S. M **[@B47]**, 2000          Nonsurgical + Surgical   Retrospective   23       1 (4.3)     NSCLC                 23         NR                                                                                   53                         12 (52.1)         Unite States

  Levitan **[@B23]**, 1998       Nonsurgical              RCT             30       2 (6.0)     NSCLC                 30         IIIB = 10(33), IV = 20 (67)                                                          64 (41-74)                 18 (60)           Unite States

  Fanucchi **[@B24]**, 1997      Nonsurgical              RCT             40       1 (2.5)     NSCLC                 40         III = 20(50), IV = 20(50)                                                            58(32-78)                  27 (68)           Unite States

  Tavecchio **[@B48]**, 1994     Nonsurgical + Surgical   Retrospective   57       2 (3.5)     NSCLC +SCLC           51         IIIA = 19 (33.3), IIIB = 38 (66.7)                                                   56 (46-70)                 53 (92.9)         Italy

  Thomas **[@B49]**, 1994        Nonsurgical + Surgical   Retrospective   15       2 (13.3)    NSCLC +SCLC           14         IIIA = 2 (13.3), IIIB = 11 (73.4), IV = 2 (13.3)                                     58 (33-71)                 14 (93.3)         France
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NOTE: NR: not reported; VTE: venous thromboembolism; PE: pulmonary embolism; RCT: randomized controlled trial; NSCLC: non-small cell lung cancer; SCLC: small cell lung cancer.
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